复发/转移性鳞状头颈部癌的新治疗方法。

IF 1.4 4区医学 Q3 OTORHINOLARYNGOLOGY

Otolaryngologic Clinics of North America Pub Date : 2025-10-03 DOI:10.1016/j.otc.2025.08.009

Sandra Llop, Pablo Jiménez-Labaig, Ilaria Micheletto, Nabil F Saba, Ben O'Leary

{"title":"复发/转移性鳞状头颈部癌的新治疗方法。","authors":"Sandra Llop, Pablo Jiménez-Labaig, Ilaria Micheletto, Nabil F Saba, Ben O'Leary","doi":"10.1016/j.otc.2025.08.009","DOIUrl":null,"url":null,"abstract":"The prognosis of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) remains poor, with most patients presenting with primary or acquired resistance to immune checkpoint inhibitors (ICIs). Upon progression on ICIs, the only standard of care treatment options are chemotherapy ± cetuximab combinations with high toxicity rates and limited efficacy, underscoring the urgent need for more effective and tolerable therapeutic strategies. This review explores the landscape of rapidly evolving novel treatment approaches in recurrent/metastatic HNSCC, including ICI combinations, therapeutic vaccines, injectable drugs, bispecific antibodies, antibody-drug conjugates, multitargeted kinase inhibitors and new targeted therapy agents.","PeriodicalId":54657,"journal":{"name":"Otolaryngologic Clinics of North America","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer.\",\"authors\":\"Sandra Llop, Pablo Jiménez-Labaig, Ilaria Micheletto, Nabil F Saba, Ben O'Leary\",\"doi\":\"10.1016/j.otc.2025.08.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The prognosis of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) remains poor, with most patients presenting with primary or acquired resistance to immune checkpoint inhibitors (ICIs). Upon progression on ICIs, the only standard of care treatment options are chemotherapy ± cetuximab combinations with high toxicity rates and limited efficacy, underscoring the urgent need for more effective and tolerable therapeutic strategies. This review explores the landscape of rapidly evolving novel treatment approaches in recurrent/metastatic HNSCC, including ICI combinations, therapeutic vaccines, injectable drugs, bispecific antibodies, antibody-drug conjugates, multitargeted kinase inhibitors and new targeted therapy agents.\",\"PeriodicalId\":54657,\"journal\":{\"name\":\"Otolaryngologic Clinics of North America\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Otolaryngologic Clinics of North America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.otc.2025.08.009\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otolaryngologic Clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.otc.2025.08.009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

复发/转移性头颈部鳞状细胞癌（HNSCC）的预后仍然很差，大多数患者表现为对免疫检查点抑制剂（ICIs）的原发性或获得性耐药性。在ICIs进展时，唯一的标准治疗选择是化疗±西妥昔单抗联合治疗，但毒性高，疗效有限，强调迫切需要更有效和可耐受的治疗策略。本综述探讨了复发/转移性HNSCC快速发展的新治疗方法，包括ICI联合治疗、治疗性疫苗、注射药物、双特异性抗体、抗体-药物偶联物、多靶向激酶抑制剂和新的靶向治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer.

The prognosis of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) remains poor, with most patients presenting with primary or acquired resistance to immune checkpoint inhibitors (ICIs). Upon progression on ICIs, the only standard of care treatment options are chemotherapy ± cetuximab combinations with high toxicity rates and limited efficacy, underscoring the urgent need for more effective and tolerable therapeutic strategies. This review explores the landscape of rapidly evolving novel treatment approaches in recurrent/metastatic HNSCC, including ICI combinations, therapeutic vaccines, injectable drugs, bispecific antibodies, antibody-drug conjugates, multitargeted kinase inhibitors and new targeted therapy agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Otolaryngologic Clinics of North America 医学-耳鼻喉科学

CiteScore

3.00

自引率

0.00%

发文量

152

审稿时长

6-12 weeks

期刊介绍： Otolaryngologic Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in otolaryngology and is presented under the direction of an experienced guest editor.